Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDVerve Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.70 | -$0.70 | -$0.70 |
| Q2 2024 | 2 | -$0.68 | -$0.68 | -$0.68 |
| Q3 2024 | 3 | -$0.68 | -$0.68 | -$0.68 |
| Q4 2024 | 8 | -$0.87 | -$0.53 | -$0.68 |
| Q1 2025 | 5 | -$0.90 | -$0.62 | -$0.73 |
| Q2 2025 | 4 | -$0.75 | -$0.75 | -$0.75 |
| Q3 2025 | 4 | -$0.76 | -$0.76 | -$0.76 |
| Q4 2025 | 4 | -$0.75 | -$0.75 | -$0.75 |
Verve Therapeutics, Inc. Earnings Date And Information
Verve Therapeutics, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-0.59 earnings per share for the quarter, topping analysts' consensus estimates of $-0.7 by $0.11. The company had revenue of 6.87 M for the quarter and had revenue of 11.76 M for the year. Verve Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-3.12 diluted earnings per share) and currently has a price-to-earnings ratio of -2.57. Verve Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Verve Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$0.70 | -$0.60 | 0.1 | $2.75 M | $6.87 M |
| 08/08/2024 | Q2 2024 | -$0.68 | -$0.59 | 0.09 | $2.40 M | $6.69 M |
| 05/08/2024 | Q1 2024 | -$0.68 | -$0.59 | 0.09 | $5.70 M | |
| 02/27/2024 | Q4 2023 | -$0.80 | -$0.69 | 0.11 | $5.14 M | |
| 11/07/2023 | Q3 2023 | -$0.91 | -$0.72 | 0.19 | $963,667 | $3.12 M |
| 08/10/2023 | Q2 2023 | -$0.91 | -$0.87 | 0.04 | $672,667 | $2.09 M |
| 05/15/2023 | Q1 2023 | -$0.78 | -$0.74 | 0.04 | $1.40 M | |
| 03/02/2023 | Q4 2022 | -$0.76 | -$0.67 | 0.09 | $1.01 M | |
| 11/07/2022 | Q3 2022 | -$0.75 | -$0.81 | -0.06 | $833,333 | $929,000 |
| 08/09/2022 | Q2 2022 | -$0.63 | -$0.82 | -0.19 | $0 | |
| 05/10/2022 | Q1 2022 | -$0.63 | -$0.58 | 0.05 | $0 | |
| 03/14/2022 | Q4 2021 | -$0.54 | -$0.65 | -0.11 | $0 | |
| 11/10/2021 | Q3 2021 | -$0.45 | -$0.47 | -0.02 | $0 | |
| 08/12/2021 | Q2 2021 | -$0.49 | -$1.10 | -0.61 | $0 | |
| 03/30/2021 | Q1 2021 | -$0.30 | $0 | |||
| 12/31/2020 | Q4 2020 | -$0.81 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.31 | $0 | |||
| 06/29/2020 | Q2 2020 | -$0.26 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.19 | $0 |
Verve Therapeutics, Inc. Earnings: FAQ's
When is Verve Therapeutics, Inc.'s earnings date?
Verve Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
Did Verve Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Verve Therapeutics, Inc. (:VERV) reported $-0.59 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.7 by $0.11.
How can I listen to Verve Therapeutics, Inc.'s earnings conference
call?
The conference call for Verve Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Verve Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Verve Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Verve Therapeutics, Inc. generate each year?
Verve Therapeutics, Inc. (:VERV) has a recorded annual revenue of $11.76 M.
How much profit does Verve Therapeutics, Inc. generate each year?
Verve Therapeutics, Inc. (:VERV) has a recorded net income of $11.76 M. Verve Therapeutics, Inc. has generated $-3.12 earnings per share over the last four quarters.
What is Verve Therapeutics, Inc.'s price-to-earnings ratio?
Verve Therapeutics, Inc. (:VERV) has a price-to-earnings ratio of -2.57 and price/earnings-to-growth ratio is -0.56.